During the past decade, Integral Rheumatology & Immunology Specialists conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 14 clinical trials were completed, i.e. on average, 73.7% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 11 clinical trials were completed. i.e. 137.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Integral Rheumatology & Immunology Specialists" #1 sponsor was "Bristol-Myers Squibb" with 5 trials, followed by "Janssen Research & Development, LLC" with 4 trials sponsored, "Amgen" with 3 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored and "Boehringer Ingelheim" with 3 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Integral Rheumatology & Immunology Specialists" #1 collaborator was "Incyte Corporation" with 2 trials as a collaborator and "Teva Pharmaceutical Industries, Ltd." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Integral Rheumatology & Immunology Specialists" are "Rheumatoid Arthritis" (5 trials), "Lupus Nephritis" (4 trials), "Systemic Lupus Erythematosus" (4 trials), "Arthritis, Psoriatic" (3 trials) and "Lupus Erythematosus, Systemic" (2 trials). Many other conditions were trialed in "Integral Rheumatology & Immunology Specialists" in a lesser frequency.

Most popular intervention types in "Integral Rheumatology & Immunology Specialists" are "Drug" (22 trials), "Other" (7 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Baricitinib" (3 trials), "Methotrexate" (3 trials), "Adalimumab" (2 trials) and "Guselkumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Integral Rheumatology & Immunology Specialists" are 22 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Integral Rheumatology & Immunology Specialists". 1 are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Integral Rheumatology & Immunology Specialists, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Integral Rheumatology & Immunology Specialists, 0 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 0 trials that are defined as “Not Applicable".